Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Metabolic Syndrome
Proteomics company announces research agreement with Baylor College of Medicine
September 27th, 2004
Power3 Medical Products, Inc., (OTCBB: PWRM) announced that it has entered into a research agreement with Baylor College of Medicine for the purpose of discovering biomarkers in serum and plasma that are of particular utility in the diagnosis and drug targeting for metabolic syndrome and associated disorders including diabetes, cardiovascular disease, hypertension, and stroke. The research covered under the agreement is the result of collaboration between Christie M. Ballantyne, MD, director of the Center for Cardiovascular Disease, Baylor College of Medicine and Ira L Goldknopf, PhD, chief scientific officer and head of the Scientific Team at Power3 Medical. ...
Source: Obesity & Diabetes Week (2004-09-27)
|
